Insight, China's Pharmaceutical Industry

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026

Novo Nordisk A/S (NYSE: NVO) announced that its innovative, long‑acting human growth hormone Sogroya (generic...

Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026

Inno Medicine announced that it has completed a Series D financing round of nearly RMB...

Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Fineline Cube Sep 10, 2026

Novo Nordisk A/S (NYSE: NVO) announced that semaglutide injection (brand name: Wegovy) has received approval...

Company Deals

Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404

Fineline Cube Sep 10, 2026

Adagene Inc. (NASDAQ: ADAG) announced a new milestone achievement in its ongoing SAFEbody antibody‑drug conjugate...

Company Drug

NMPA Accepts Hengrui’s New Drug Application for Ribupatide Injection – Dual GLP‑1/GIP Receptor Agonist Nears Approval for Type 2 Diabetes in China

Fineline Cube Sep 10, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that the New Drug Application...

Company Deals

Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers

Fineline Cube Sep 10, 2026

Lee’s Pharmaceutical Holdings Limited (HKG: 0950) announced that it has entered into an exclusive licensing...

Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026

METiS Therapeutics (HKG: 7666) holding company METiS Life Sciences and JOINN Biologics officially signed a...

Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026

Merck & Co., Inc. (MSD; NYSE: MRK) announced that clesrovimab injection, the world’s first single...

Company Drug

CSPC Wins NMPA Clinical Trial Approvals for Two Long‑Acting Injections – Weekly Rotigotine (SYH9087) for Parkinson’s Disease and World’s First Ready‑to‑Use Monthly Goserelin (SYH9102) for Solid Tumours

Fineline Cube Sep 10, 2026

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that two long‑acting injection products have obtained approval...

Company Deals

HBM Partner Solstice Oncology Launches with US$225 Million Series A Led by RA Capital – Advancing Second‑Generation CTLA‑4 Antibody Porustobart in Neoadjuvant Oncology

Fineline Cube Sep 10, 2026

HBM Holdings Limited (HKG: 2142) announced that its partner company, Solstice Oncology, has completed a...

Company Drug

NMPA Accepts Yantai Dongcheng’s Marketing Application for Bemiparin Sodium Injection – Potential First Generic of Ultra‑Low Molecular Weight Heparin in China

Fineline Cube Sep 10, 2026

Yantai Dongcheng Pharmaceutical Group Co., Ltd. (SHE: 002675) announced that China’s National Medical Products Administration...

Company Deals

Moonwalk Biosciences Closes Oversubscribed USD 70 Million Series B – Eli Lilly Joins Alpha Wave and YK Bioventures to Back First‑in‑Class Adipose‑Targeted siRNA Candidate MW101

Fineline Cube Sep 10, 2026

Moonwalk Biosciences, a partner of Siran Bio, announced the completion of an oversubscribed USD 70...

Company Drug

Full-Life Technologies Secures FDA IND Clearance for [²²⁵Ac]Ac‑FL‑261 – Potential First‑in‑Class c‑MET Alpha Radionuclide Conjugate Enters Phase I in Non‑Squamous NSCLC

Fineline Cube Sep 10, 2026

Full-Life Technologies Limited announced that its Investigational New Drug (IND) application for Ac‑FL‑261 has been...

Company Deals PIC

CellStore Signs Strategic Partnership Memorandum With Shanghai Cell Therapy Group – Deepening Cooperation in Cell Cryopreservation, Product Application Validation, and Industrial Synergy Across Cell and Gene Therapy

Fineline Cube Sep 10, 2026

CellStore signed a Memorandum of Strategic Partnership with Shanghai Cell Therapy Group, under which the...

Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Fineline Cube Sep 9, 2026

The Becton, Dickinson and Co. (BD) (Tianjin) Life Health Innovation Center officially opened its doors...

Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Fineline Cube Sep 9, 2026

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that SYH2083 eye drops, its Class 1 innovative...

Company

Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030

Fineline Cube Sep 9, 2026

Gilead Sciences, Inc. (NASDAQ: GILD) announced the opening of its 182,000‑square‑foot Research Center at the...

Company Drug

Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins

Fineline Cube Sep 9, 2026

HBM Holdings Limited (HKG: 2142) announced that Windward Bio AG, the company’s partner, has reported...

Policy / Regulatory

China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity

Fineline Cube Sep 9, 2026

China’s National Health Commission (NHC) issued the Work Plan to Accelerate the Provision of High‑Quality...

Company Drug

Ascletis Pharma Initiates US Phase 1 Study of ASC36 Oral Tablets – An Oral Amylin Receptor Agonist for Obesity, Advancing a Dual‑Format Program Alongside Its Once‑Monthly Injectable

Fineline Cube Sep 9, 2026

Ascletis Pharma Inc. (HKG: 1672) announced the initiation of a US Phase 1 study of...

You Missed